Mocetinostat - Mirati Therapeutics

Drug Profile

Mocetinostat - Mirati Therapeutics

Alternative Names: MG-0103; MGCD-0103; MGCD103; Mocetinostat dihydrobromide

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MethylGene
  • Developer MedImmune; MethylGene; Mirati Therapeutics; New York University School of Medicine
  • Class Antineoplastics; Benzamides; Pyrimidines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes; Diffuse large B cell lymphoma; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Malignant melanoma
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Acute myeloid leukaemia; Hodgkin's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Apr 2018 Phase-I clinical trials in Malignant melanoma (Combination therapy, Late-stage disease) in USA (PO) (NCT03565406)
  • 31 Mar 2018 Adverse events and efficacy data from a phase II trial in Non-small cell lung cancer released by Mirati Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top